Myopia Treatment Devices Market

Author : John snow | Published On : 03 Apr 2026

The market for myopia treatment devices is witnessing notable momentum, largely supported by the rising incidence of myopia and high myopia worldwide. Continuous advancements in vision correction technologies, increasing awareness regarding early diagnosis and preventive eye care, and the strong focus on product innovation by major industry players are further strengthening market growth. The growth trajectory of the myopia treatment devices market is being shaped by a combination of factors, including the escalating burden of myopia cases, technological breakthroughs in treatment devices, increasing focus on preventive healthcare, and the expansion of research and development initiatives by leading companies.

New York, USA, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Myopia Treatment Devices Market Set for Robust Expansion at ~8% CAGR Through 2032, Fueled by Innovation and Rising Demand for Eye Care Solutions | DelveInsight

DelveInsight’s Myopia Treatment Devices Market Insights report delivers a comprehensive evaluation of current trends and future projections, alongside an analysis of leading companies, their market shares, growth drivers, challenges, and emerging opportunities in the competitive landscape. The myopia treatment devices market is projected to grow significantly, increasing from approximately USD 12 billion in 2024 to nearly USD 18 billion by 2032, indicating a steady and sustained upward trend, and is anticipated to expand at a CAGR of around 8% during the forecast period from 2025 to 2032. Key players operating in this space include CooperVision (CooperCompanies), Johnson & Johnson Services Inc., Essilor, Bausch & Lomb Incorporated, Menicon Co., Ltd., LUCID KOREA LTD., Alcon Inc., HOYA VISION CARE COMPANY, SynergEyes, SightGlass Vision, Inc., Ophtec BV, STAAR SURGICAL, Mark'ennovy, SCHWIND eye-tech-solutions, Euclid Systems Corporation, NIDEK USA, Inc., Esahorus srl, Falco lenses AG, and others. North America is expected to witness the fastest growth rate during the forecast period, while within product segmentation, glasses dominated the market share in 2024.

To read more about the latest highlights related to the myopia treatment devices market, get a snapshot of the key highlights entailed in the Global Myopia Treatment Devices Market Forecast Report

The increasing number of individuals affected by myopia, especially among children and young adults, is a major factor driving demand for treatment devices. Modern lifestyle patterns, including extended screen usage, reduced outdoor exposure, and increased engagement in near-vision activities such as reading and digital work, have significantly contributed to the rise in refractive errors, creating sustained demand for effective corrective and preventive solutions. Continuous innovation in treatment technologies has enhanced the effectiveness and usability of myopia management devices, with developments in orthokeratology lenses, pharmacological treatments like atropine drops, and advanced contact lens designs improving patient comfort and treatment outcomes and encouraging adoption by both patients and healthcare professionals.

Greater awareness regarding eye health and the importance of early intervention is playing a vital role in market expansion, as educational campaigns and healthcare initiatives inform the public about the long-term risks of untreated myopia. As a result, parents and caregivers are increasingly seeking early treatment options to slow disease progression in children. At the same time, the availability of advanced healthcare infrastructure, including specialized eye care centers and trained ophthalmologists, is supporting market growth through improved diagnostic capabilities and access to modern treatment devices, enabling better patient management and follow-up care. Favorable reimbursement policies in several regions are also making myopia management devices more accessible, reducing financial burden and encouraging adoption of advanced treatment options, thereby boosting overall market penetration.

Rapid urbanization is closely linked to increasing myopia prevalence, as urban lifestyles often involve prolonged indoor activities and limited exposure to natural light, both of which are associated with higher rates of myopia. As urban populations continue to expand, especially in developing regions, the demand for myopia treatment solutions is expected to rise correspondingly.

Get a sneak peek at the myopia treatment devices market dynamics @ Myopia Treatment Devices Market Trends

North America accounted for the largest share of the myopia treatment devices market in 2024, contributing approximately 34% of the total market, driven by a high prevalence of vision disorders, well-established healthcare infrastructure, and continuous technological innovation, along with strong awareness regarding eye health and supportive reimbursement systems that facilitate adoption of advanced treatment devices. Europe also represents a significant portion of the market, benefiting from a mature healthcare ecosystem and high levels of awareness about eye care, supported by a well-developed network of ophthalmology clinics offering a wide range of treatment options, including traditional corrective lenses, laser-based procedures, and innovative myopia control solutions. Meanwhile, the Asia-Pacific region is emerging as a key growth hub, driven by the rapidly increasing incidence of myopia, particularly among younger populations in countries such as China, Japan, South Korea, and India, where factors like excessive screen time, academic pressure, and limited outdoor activities are contributing to a surge in cases and generating substantial demand for both corrective and preventive devices.

To know more about why North America is leading the market growth in the myopia treatment devices market, get a snapshot of the Myopia Treatment Devices Market Share

Recent innovations and regulatory approvals highlight the dynamic nature of the myopia treatment devices market. In August 2025, CooperVision received approval from Japan’s Ministry of Health, Labor, and Welfare for its MiSight 1-day contact lenses, marking the first soft lens in the country approved for children to both correct myopia and manage its progression. In June 2025, France became the first EU nation to introduce reimbursement for HOYA MiYOSMART spectacle lenses, enabling children aged 5 to 16 with progressive myopia to access these lenses under reimbursement schemes. In March 2025, Bausch + Lomb Corporation launched the Arise lens-fitting system in the United States, leveraging cloud-based technology to enable rapid and precise orthokeratology lens design, along with FDA-approved ortho-K lenses featuring toric peripheral curves for overnight treatment. In January 2025, ZEISS Medical Technology secured FDA approval for its MEL 90 excimer laser system, enabling its use across multiple indications, including myopia, hyperopia, and mixed astigmatism.

Myopia treatment devices are increasingly being utilized as effective tools to manage nearsightedness and slow its progression. Among the most prominent solutions are orthokeratology (Ortho-K) lenses, which are specially engineered rigid contact lenses worn overnight to temporarily reshape the cornea, allowing individuals to experience clear vision during the day without relying on glasses or contact lenses. In addition to Ortho-K lenses, specialized soft contact lenses such as multifocal and dual-focus designs have been developed to address myopia progression, particularly in children, working by reducing peripheral hyperopic defocus, a key factor associated with eye elongation and worsening myopia. Overall, these devices not only enhance visual acuity but also target the underlying physiological mechanisms responsible for myopia progression, making them a critical component of modern eye care strategies.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

DelveInsight's "Myopia - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Myopia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Some of the key Myopia Treatment Devices Companies in the market include CooperVision (CooperCompanies), Johnson & Johnson, Essilor, Bausch & Lomb Incorporated, Menicon Co., Ltd., LUCID KOREA LTD., Alcon Inc., HOYA VISION CARE COMPANY, SynergEyes., SightGlass Vision, Inc., Ophtec BV, STAAR SURGICAL, Mark'ennovy, SCHWIND eye-tech-solutions, Euclid Systems Corporation, NIDEK USA, Inc., HORUS S.n.C. di Risoldi & C – P, Falco lenses AG, and others.

Myopia - Pipeline Insight, 2026

DelveInsight’s, “Myopia - Pipeline Insight, 2026” report provides comprehensive insights about 8+ companies and 10+ pipeline drugs in Myopia pipeline landscape. Some of the key Myopia Treatment Devices Companies in the market include CooperVision (CooperCompanies), Johnson & Johnson, Essilor, Bausch & Lomb Incorporated, Menicon Co., Ltd., LUCID KOREA LTD., Alcon Inc., HOYA VISION CARE COMPANY, SynergEyes., SightGlass Vision, Inc., Ophtec BV, STAAR SURGICAL, Mark'ennovy, SCHWIND eye-tech-solutions, Euclid Systems Corporation, NIDEK USA, Inc., HORUS S.n.C. di Risoldi & C – P, Falco lenses AG, and others.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Abhishek kumar

Email: [email protected]

City: Albany

State: New York

Country: United States

Website: https://www.delveinsight.com